Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung

被引：13

作者：

Bernicker, Eric H. ^{[1
]}

Miller, Ross A. ^{[1
]}

Cagle, Phillip T. ^{[1
]}

机构：

[1] Houston Methodist Hosp, Houston, TX USA

来源：

JOURNAL OF ONCOLOGY PRACTICE | 2017年 / 13卷 / 04期

关键词：

ACQUIRED-RESISTANCE; OPEN-LABEL; CLINICAL CHARACTERISTICS; CANCER PATIENTS; EGFR MUTATIONS; HER2; MUTATION; CRIZOTINIB; CHEMOTHERAPY; MULTICENTER; ROS1;

D O I：

10.1200/JOP.2016.019182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

To suggest that the discovery of targetable driver mutations in many patients with advanced adenocarcinoma of the lung has completely transformed the work-up and therapeutic options for this disease would not be hyperbole. Although not curative, smallmolecule tyrosine kinase inhibitors directed at oncogene-addicted tumors have led to significantly improved response rates compared with cytotoxic chemotherapy, with often manageable toxicities and better tolerance. However, the absence of reliable clinical predictors has made molecular testing essential to ensure that patients receive the proper medical management. We outline the many recent advances with regard to diagnosis and treatment of oncogene-addicted advanced nonsquamous non-small-cell lung cancer.

引用

页码：221 / +

页数：8

共 49 条

[1]

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[2]

Awad MM, 2013, NEW ENGL J MED, V369, P1173, DOI [10.1056/NEJMc1309091, 10.1056/NEJMoa1215530]

[3]

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].

Beau-Faller, M. ;

Prim, N. ;

Ruppert, A. -M. ;

Nanni-Metellus, I. ;

Lacave, R. ;

Lacroix, L. ;

Escande, F. ;

Lizard, S. ;

Pretet, J. -L ;

Rouquette, I. ;

de Cremoux, P. ;

Solassol, J. ;

de Fraipont, F. ;

Bieche, I. ;

Cayre, A. ;

Favre-Guillevin, E. ;

Tomasini, P. ;

Wislez, M. ;

Besse, B. ;

Legrain, M. ;

Voegeli, A. -C. ;

Baudrin, L. ;

Morin, F. ;

Zalcman, G. ;

Quoix, E. ;

Blons, H. ;

Cadranel, J. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131

[4]

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[5]

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[6]

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas [J].

Drilon, Alexander ;

Wang, Lu ;

Hasanovic, Adnan ;

Suehara, Yoshiyuki ;

Lipson, Doron ;

Stephens, Phil ;

Ross, Jeffrey ;

Miller, Vincent ;

Ginsberg, Michelle ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc ;

Rizvi, Naiyer .

CANCER DISCOVERY, 2013, 3 (06) :630-635

[7]

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[8]

The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer [J].

Gainor, Justin F. ;

Ou, Sai-Hong Ignatius ;

Logan, Jennifer ;

Borges, Lawrence F. ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) :1570-1573

[9]

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions [J].

Gainor, Justin F. ;

Shaw, Alice T. .

ONCOLOGIST, 2013, 18 (07) :865-875

[10]

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott ;

Rizvi, Naiyer A. ;

Chow, Laura Q. ;

Borghaei, Hossein ;

Brahmer, Julie ;

Ready, Neal ;

Gerber, David E. ;

Shepherd, Frances A. ;

Antonia, Scott ;

Goldman, JonathanW. ;

Juergens, Rosalyn A. ;

Laurie, Scott A. ;

Nathan, Faith E. ;

Shen, Yun ;

Harbison, Christopher T. ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2980-+

← 1 2 3 4 5 →